Get the Stockscreener App
135.14
0.21%
-0.29
After Hours:
135.14
Jazz Pharmaceuticals Plc stock is traded at $135.14, with a volume of 369.29K.
It is down -0.21% in the last 24 hours and up +7.12% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$135.43
Open:
$135.83
24h Volume:
369.29K
Relative Volume:
0.50
Market Cap:
$8.20B
Revenue:
$4.09B
Net Income/Loss:
$-404.84M
P/E Ratio:
-20.03
EPS:
-6.7469
Net Cash Flow:
$1.24B
1W Performance:
-1.77%
1M Performance:
+7.12%
6M Performance:
+34.47%
1Y Performance:
+24.21%
1-Day Range:
$133.48
$136.25
1-Week Range:
$133.48
$139.44
52-Week Range:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
135.14 | 8.22B | 4.09B | -404.84M | 1.24B | -6.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Order flow analysis tools used on Jazz Pharmaceuticals plcJuly 2025 Snapshot & Consistent Income Trade Recommendations - newser.com
Is Jazz Pharmaceuticals plc stock a buy before product launches2025 Market Outlook & Stepwise Entry and Exit Trade Signals - newser.com
Is Jazz Pharmaceuticals plc stock attractive for passive investorsWeekly Trend Summary & Safe Entry Trade Signal Reports - newser.com
What institutional flow reveals about Jazz Pharmaceuticals plcPortfolio Risk Summary & Long-Term Safe Investment Plans - newser.com
Is Jazz Pharmaceuticals plc showing signs of accumulation2025 Technical Overview & Technical Pattern Alert System - newser.com
Jazz Pharmaceuticals plc’s volatility index tracking explained2025 EndofYear Setup & Fast Momentum Entry Tips - newser.com
Will Jazz Pharmaceuticals plc benefit from macro trendsGap Up & Free Reliable Trade Execution Plans - newser.com
Forecasting Jazz Pharmaceuticals plc price range with options dataEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
How strong is Jazz Pharmaceuticals plc stock revenue growthEntry Point & Low Drawdown Trading Strategies - newser.com
Jazz Pharmaceuticals plc stock outlook for YEARMarket Risk Report & Daily Growth Stock Tips - newser.com
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: A 38% Upside Potential with Robust Analyst Support - DirectorsTalk Interviews
Full technical analysis of Jazz Pharmaceuticals plc stockWeekly Volume Report & Smart Money Movement Alerts - newser.com
Published on: 2025-10-12 20:45:57 - newser.com
Assessing Jazz Pharmaceuticals (JAZZ) Valuation Following Strong Recent Share Price Momentum - Yahoo
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Meritage Portfolio Management - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat
Jazz Pharmaceuticals (JAZZ): Assessing Valuation Following Recent Net Income Growth and Share Price Recovery - simplywall.st
Zacks Research Has Positive Forecast for JAZZ Q2 Earnings - MarketBeat
Lmcg Investments LLC Lowers Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Cannabis Market Trends and Company Analysis 2025-2033 Featuring Canopy Growth, Tilray Brands, Curaleaf, Aurora, Jazz Pharma, Green Thumb Industries, Trulieve, Cresco Labs, Organigram, TerrAscend - Yahoo Finance
United States Idiopathic Hypersomnia Treatment Market: Jazz Pharmaceuticals & Emerging Competitors - openPR.com
Leerink Partnrs Has Bearish Estimate for JAZZ Q3 Earnings - MarketBeat
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Truist Financial - The Globe and Mail
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Bank of America Securities - The Globe and Mail
Will Jazz Pharmaceuticals plc stock keep outperforming rivalsBuy Signal & Safe Capital Growth Plans - newser.com
BofA Adjusts Price Target on Jazz Pharmaceuticals Public to $230 From $225 - MarketScreener
Weiss Ratings Reiterates "Sell (D)" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - MarketBeat
Is Jazz Pharmaceuticals plc a candidate for recovery playMarket Trend Review & High Conviction Buy Zone Picks - newser.com
Tick level data insight on Jazz Pharmaceuticals plc volatility2025 Year in Review & High Accuracy Trade Alerts - newser.com
Lewy Body Dementia Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Jazz Pharma, Allergan, Noven Pharma, Takeda Pharma, Eli Lilly, Mallinckrodt Pharma - Barchart.com
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer - Yahoo Finance
Will Jazz Pharmaceuticals plc (J7Z) stock remain on Wall Street radarTake Profit & Long-Term Capital Growth Strategies - newser.com
Will Jazz Pharmaceuticals plc (J7Z) stock announce special dividend - newser.com
What MACD and RSI say about Jazz Pharmaceuticals plc2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Are Shares of Jazz Pharmaceuticals Set for Growth After Strong Q2 Results in 2025? - simplywall.st
Why Jazz Pharmaceuticals plc (J7Z) stock could be top winnerQuarterly Profit Summary & High Accuracy Investment Entry Signals - newser.com
Robeco Institutional Asset Management B.V. Sells 92,794 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data - MSN
M&A Snapshot: Jazz Pharmaceuticals acquires Chimerix at a 72% premium deal - MSN
Polaris Capital Management LLC Decreases Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 2,000 Shares of Stock - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 3,500 Shares - MarketBeat
Insider Sell: Bruce Cozadd Sells 5,500 Shares of Jazz Pharmaceuticals PLC - GuruFocus
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio - MSN
Jazz Looks To Label Expansion To Reverse Zepzelca Sales Slump - insights.citeline.com
Why Jazz Pharmaceuticals (JAZZ) Is Up 7.4% After Groundbreaking FDA Approval for First-Line Lung Cancer Therapy - simplywall.st
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):